Does the media refer more to BNGO or HBIO?

In the previous week, Harvard Bioscience had 7 more articles in the media than Bionano Genomics. MarketBeat recorded 15 mentions for Harvard Bioscience and 8 mentions for Bionano Genomics. Harvard Bioscience's average media sentiment score of 0.56 beat Bionano Genomics' score of 0.54 indicating that Harvard Bioscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bionano Genomics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Harvard Bioscience 1 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend BFRG or BNGO?

Bionano Genomics has a consensus price target of $6.00, indicating a potential upside of 408.47%. Given Bionano Genomics' stronger consensus rating and higher probable upside, analysts plainly believe Bionano Genomics is more favorable than Bullfrog AI. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bullfrog AI 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Bionano Genomics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is BFRG or BNGO more profitable?

Bullfrog AI has a net margin of 0.00% compared to Bionano Genomics' net margin of -106.58%. Bionano Genomics' return on equity of -78.78% beat Bullfrog AI's return on equity. Company Net Margins Return on Equity Return on Assets Bullfrog AI N/A -217.80% -174.57% Bionano Genomics -106.58% -78.78% -48.54%

Does the media favor BFRG or BNGO?

In the previous week, Bionano Genomics had 4 more articles in the media than Bullfrog AI. MarketBeat recorded 8 mentions for Bionano Genomics and 4 mentions for Bullfrog AI. Bullfrog AI's average media sentiment score of 1.22 beat Bionano Genomics' score of 0.54 indicating that Bullfrog AI is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bullfrog AI 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bionano Genomics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend ISPC or BNGO?

Bionano Genomics has a consensus target price of $6.00, indicating a potential upside of 408.47%. Given Bionano Genomics' stronger consensus rating and higher probable upside, analysts clearly believe Bionano Genomics is more favorable than iSpecimen. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score iSpecimen 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Bionano Genomics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is ISPC or BNGO more profitable?

Bionano Genomics has a net margin of -106.58% compared to iSpecimen's net margin of -1,080.16%. Bionano Genomics' return on equity of -78.78% beat iSpecimen's return on equity. Company Net Margins Return on Equity Return on Assets iSpecimen -1,080.16% -584.65% -142.48% Bionano Genomics -106.58% -78.78% -48.54%

Does the media prefer ISPC or BNGO?

In the previous week, Bionano Genomics had 5 more articles in the media than iSpecimen. MarketBeat recorded 8 mentions for Bionano Genomics and 3 mentions for iSpecimen. Bionano Genomics' average media sentiment score of 0.54 beat iSpecimen's score of 0.54 indicating that Bionano Genomics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iSpecimen 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bionano Genomics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer VIVS or BNGO?

Bionano Genomics has a consensus price target of $6.00, suggesting a potential upside of 408.47%. Given Bionano Genomics' stronger consensus rating and higher possible upside, analysts clearly believe Bionano Genomics is more favorable than VivoSim Labs. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score VivoSim Labs 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Bionano Genomics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is VIVS or BNGO more profitable?

Bionano Genomics has a net margin of -106.58% compared to VivoSim Labs' net margin of -11,016.07%. Bionano Genomics' return on equity of -78.78% beat VivoSim Labs' return on equity. Company Net Margins Return on Equity Return on Assets VivoSim Labs -11,016.07% -612.23% -177.02% Bionano Genomics -106.58% -78.78% -48.54%

Does the media favor VIVS or BNGO?

In the previous week, Bionano Genomics had 4 more articles in the media than VivoSim Labs. MarketBeat recorded 8 mentions for Bionano Genomics and 4 mentions for VivoSim Labs. Bionano Genomics' average media sentiment score of 0.54 beat VivoSim Labs' score of -0.02 indicating that Bionano Genomics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment VivoSim Labs 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Bionano Genomics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate BNGO or TBIO?

Bionano Genomics presently has a consensus price target of $6.00, suggesting a potential upside of 408.47%. Given Bionano Genomics' stronger consensus rating and higher probable upside, research analysts plainly believe Bionano Genomics is more favorable than Telesis Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bionano Genomics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Telesis Bio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Bionano Genomics (BNGO) Competitors

$1.18 0.00 (0.00%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$1.16 -0.01 (-1.27%)

As of 08/14/2026 07:58 PM Eastern

Compare

BNGO vs. HBIO, BFRG, ISPC, VIVS, and TBIO

Should you buy Bionano Genomics stock or one of its competitors? Bionano Genomics's main competitors and comparable companies include Harvard Bioscience (HBIO), Bullfrog AI (BFRG), iSpecimen (ISPC), VivoSim Labs (VIVS), and Telesis Bio (TBIO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Bionano Genomics compare to Harvard Bioscience?

Bionano Genomics (NASDAQ:BNGO) and Harvard Bioscience (NASDAQ:HBIO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, media sentiment, valuation and institutional ownership.

Bionano Genomics has higher earnings, but lower revenue than Harvard Bioscience. Harvard Bioscience is trading at a lower price-to-earnings ratio than Bionano Genomics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bionano Genomics	$30.18M	0.46	-$26.40M	-$3.02	N/A
Harvard Bioscience	$86.55M	0.35	-$56.70M	-$2.31	N/A

Bionano Genomics has a beta of 1.63, indicating that its share price is 63% more volatile than the broader market. Comparatively, Harvard Bioscience has a beta of 1.49, indicating that its share price is 49% more volatile than the broader market.

Bionano Genomics currently has a consensus price target of $6.00, suggesting a potential upside of 408.47%. Harvard Bioscience has a consensus price target of $6.75, suggesting a potential upside of 1.35%. Given Bionano Genomics' higher probable upside, equities analysts clearly believe Bionano Genomics is more favorable than Harvard Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bionano Genomics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Harvard Bioscience	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Harvard Bioscience has a net margin of -11.86% compared to Bionano Genomics' net margin of -106.58%. Harvard Bioscience's return on equity of -33.13% beat Bionano Genomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bionano Genomics	-106.58%	-78.78%	-48.54%
Harvard Bioscience	-11.86%	-33.13%	-4.80%

In the previous week, Harvard Bioscience had 7 more articles in the media than Bionano Genomics. MarketBeat recorded 15 mentions for Harvard Bioscience and 8 mentions for Bionano Genomics. Harvard Bioscience's average media sentiment score of 0.56 beat Bionano Genomics' score of 0.54 indicating that Harvard Bioscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bionano Genomics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Harvard Bioscience	1 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

11.4% of Bionano Genomics shares are held by institutional investors. Comparatively, 80.9% of Harvard Bioscience shares are held by institutional investors. 0.7% of Bionano Genomics shares are held by company insiders. Comparatively, 17.0% of Harvard Bioscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Harvard Bioscience beats Bionano Genomics on 9 of the 14 factors compared between the two stocks.

How does Bionano Genomics compare to Bullfrog AI?

Bullfrog AI (NASDAQ:BFRG) and Bionano Genomics (NASDAQ:BNGO) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, earnings, risk, profitability, institutional ownership, dividends and valuation.

Bullfrog AI has a beta of -2.7, indicating that its stock price is 370% less volatile than the broader market. Comparatively, Bionano Genomics has a beta of 1.63, indicating that its stock price is 63% more volatile than the broader market.

1.0% of Bullfrog AI shares are owned by institutional investors. Comparatively, 11.4% of Bionano Genomics shares are owned by institutional investors. 14.7% of Bullfrog AI shares are owned by insiders. Comparatively, 0.7% of Bionano Genomics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Bullfrog AI has a net margin of 0.00% compared to Bionano Genomics' net margin of -106.58%. Bionano Genomics' return on equity of -78.78% beat Bullfrog AI's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bullfrog AI	N/A	-217.80%	-174.57%
Bionano Genomics	-106.58%	-78.78%	-48.54%

Bionano Genomics has a consensus price target of $6.00, indicating a potential upside of 408.47%. Given Bionano Genomics' stronger consensus rating and higher probable upside, analysts plainly believe Bionano Genomics is more favorable than Bullfrog AI.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bullfrog AI	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Bionano Genomics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Bionano Genomics had 4 more articles in the media than Bullfrog AI. MarketBeat recorded 8 mentions for Bionano Genomics and 4 mentions for Bullfrog AI. Bullfrog AI's average media sentiment score of 1.22 beat Bionano Genomics' score of 0.54 indicating that Bullfrog AI is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bullfrog AI	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bionano Genomics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Bullfrog AI has higher earnings, but lower revenue than Bionano Genomics. Bullfrog AI is trading at a lower price-to-earnings ratio than Bionano Genomics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bullfrog AI	$120K	87.79	-$6.50M	-$0.54	N/A
Bionano Genomics	$30.18M	0.46	-$26.40M	-$3.02	N/A

Summary

Bionano Genomics beats Bullfrog AI on 10 of the 16 factors compared between the two stocks.

How does Bionano Genomics compare to iSpecimen?

iSpecimen (NASDAQ:ISPC) and Bionano Genomics (NASDAQ:BNGO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, institutional ownership, earnings, media sentiment, profitability and risk.

In the previous week, Bionano Genomics had 5 more articles in the media than iSpecimen. MarketBeat recorded 8 mentions for Bionano Genomics and 3 mentions for iSpecimen. Bionano Genomics' average media sentiment score of 0.54 beat iSpecimen's score of 0.54 indicating that Bionano Genomics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iSpecimen	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bionano Genomics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

iSpecimen has higher earnings, but lower revenue than Bionano Genomics. Bionano Genomics is trading at a lower price-to-earnings ratio than iSpecimen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iSpecimen	$1.93M	1.77	-$10.49M	-$72.26	N/A
Bionano Genomics	$30.18M	0.46	-$26.40M	-$3.02	N/A

Bionano Genomics has a consensus target price of $6.00, indicating a potential upside of 408.47%. Given Bionano Genomics' stronger consensus rating and higher probable upside, analysts clearly believe Bionano Genomics is more favorable than iSpecimen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iSpecimen	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Bionano Genomics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

iSpecimen has a beta of 1.66, indicating that its stock price is 66% more volatile than the broader market. Comparatively, Bionano Genomics has a beta of 1.63, indicating that its stock price is 63% more volatile than the broader market.

Bionano Genomics has a net margin of -106.58% compared to iSpecimen's net margin of -1,080.16%. Bionano Genomics' return on equity of -78.78% beat iSpecimen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iSpecimen	-1,080.16%	-584.65%	-142.48%
Bionano Genomics	-106.58%	-78.78%	-48.54%

13.6% of iSpecimen shares are held by institutional investors. Comparatively, 11.4% of Bionano Genomics shares are held by institutional investors. 12.2% of iSpecimen shares are held by insiders. Comparatively, 0.7% of Bionano Genomics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Bionano Genomics beats iSpecimen on 10 of the 16 factors compared between the two stocks.

How does Bionano Genomics compare to VivoSim Labs?

VivoSim Labs (NASDAQ:VIVS) and Bionano Genomics (NASDAQ:BNGO) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation, media sentiment and analyst recommendations.

In the previous week, Bionano Genomics had 4 more articles in the media than VivoSim Labs. MarketBeat recorded 8 mentions for Bionano Genomics and 4 mentions for VivoSim Labs. Bionano Genomics' average media sentiment score of 0.54 beat VivoSim Labs' score of -0.02 indicating that Bionano Genomics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
VivoSim Labs	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bionano Genomics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

8.2% of VivoSim Labs shares are held by institutional investors. Comparatively, 11.4% of Bionano Genomics shares are held by institutional investors. 2.5% of VivoSim Labs shares are held by insiders. Comparatively, 0.7% of Bionano Genomics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

VivoSim Labs has higher earnings, but lower revenue than Bionano Genomics. Bionano Genomics is trading at a lower price-to-earnings ratio than VivoSim Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VivoSim Labs	$130K	29.92	-$13.84M	-$4.47	N/A
Bionano Genomics	$30.18M	0.46	-$26.40M	-$3.02	N/A

Bionano Genomics has a consensus price target of $6.00, suggesting a potential upside of 408.47%. Given Bionano Genomics' stronger consensus rating and higher possible upside, analysts clearly believe Bionano Genomics is more favorable than VivoSim Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VivoSim Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Bionano Genomics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Bionano Genomics has a net margin of -106.58% compared to VivoSim Labs' net margin of -11,016.07%. Bionano Genomics' return on equity of -78.78% beat VivoSim Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VivoSim Labs	-11,016.07%	-612.23%	-177.02%
Bionano Genomics	-106.58%	-78.78%	-48.54%

VivoSim Labs has a beta of 1.47, meaning that its stock price is 47% more volatile than the broader market. Comparatively, Bionano Genomics has a beta of 1.63, meaning that its stock price is 63% more volatile than the broader market.

Summary

Bionano Genomics beats VivoSim Labs on 12 of the 16 factors compared between the two stocks.

How does Bionano Genomics compare to Telesis Bio?

Bionano Genomics (NASDAQ:BNGO) and Telesis Bio (NASDAQ:TBIO) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.

Bionano Genomics has higher earnings, but lower revenue than Telesis Bio. Bionano Genomics is trading at a lower price-to-earnings ratio than Telesis Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bionano Genomics	$30.18M	0.46	-$26.40M	-$3.02	N/A
Telesis Bio	$225.09M	0.00	-$47.72M	-$20.52	N/A

Bionano Genomics has a net margin of -106.58% compared to Telesis Bio's net margin of -336.59%. Telesis Bio's return on equity of 0.00% beat Bionano Genomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bionano Genomics	-106.58%	-78.78%	-48.54%
Telesis Bio	-336.59%	N/A	-61.89%

Bionano Genomics presently has a consensus price target of $6.00, suggesting a potential upside of 408.47%. Given Bionano Genomics' stronger consensus rating and higher probable upside, research analysts plainly believe Bionano Genomics is more favorable than Telesis Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bionano Genomics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Telesis Bio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

11.4% of Bionano Genomics shares are held by institutional investors. Comparatively, 37.6% of Telesis Bio shares are held by institutional investors. 0.7% of Bionano Genomics shares are held by company insiders. Comparatively, 24.5% of Telesis Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Bionano Genomics had 8 more articles in the media than Telesis Bio. MarketBeat recorded 8 mentions for Bionano Genomics and 0 mentions for Telesis Bio. Bionano Genomics' average media sentiment score of 0.54 beat Telesis Bio's score of 0.00 indicating that Bionano Genomics is being referred to more favorably in the media.

Company	Overall Sentiment
Bionano Genomics	Positive
Telesis Bio	Neutral

Bionano Genomics has a beta of 1.63, indicating that its share price is 63% more volatile than the broader market. Comparatively, Telesis Bio has a beta of 2.43, indicating that its share price is 143% more volatile than the broader market.

Summary

Bionano Genomics beats Telesis Bio on 10 of the 16 factors compared between the two stocks.

Get Bionano Genomics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BNGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BNGO vs. The Competition

Export

Metric	Bionano Genomics	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$13.90M	$9.65B	$7.03B	$13.06B
Dividend Yield	N/A	1.46%	2.57%	10.44%
P/E Ratio	-0.39	60.32	268.81	25.28
Price / Sales	0.46	105.50	574.46	75.26
Price / Cash	N/A	26.25	70.48	50.90
Price / Book	0.44	37.50	12.91	6.24
Net Income	-$26.40M	$56.66B	$3.45B	$347.60M
7 Day Performance	1.72%	0.30%	1.11%	1.06%
1 Month Performance	-0.84%	1.38%	1.33%	0.81%
1 Year Performance	-61.18%	17.34%	62.44%	20.90%

Bionano Genomics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BNGO Bionano Genomics	1.7138 of 5 stars	$1.18 flat	$6.00 +408.5%	-63.2%	$13.90M	$30.18M	N/A	300	Earnings Report
HBIO Harvard Bioscience	0.7164 of 5 stars	$6.39 +0.0%	$6.00 -6.1%	+36.1%	$28.83M	$86.55M	N/A	490	Earnings Report Analyst Forecast
BFRG Bullfrog AI	1.5442 of 5 stars	$0.61 +4.3%	N/A	-55.6%	$11.22M	$116.67K	N/A	4	News Coverage Positive News Earnings Report
ISPC iSpecimen	0.5478 of 5 stars	$2.26 +0.9%	N/A	-95.2%	$3.44M	$1.93M	N/A	60	News Coverage Earnings Report Gap Up
VIVS VivoSim Labs	0.1493 of 5 stars	$0.36 -0.4%	N/A	-82.1%	$1.27M	$131K	N/A	20	Earnings Report Short Interest Increase

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BNGO) was last updated on 8/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bionano Genomics (BNGO) Competitors

BNGO vs. HBIO, BFRG, ISPC, VIVS, and TBIO

How does Bionano Genomics compare to Harvard Bioscience?

Summary

How does Bionano Genomics compare to Bullfrog AI?

Summary

How does Bionano Genomics compare to iSpecimen?

Summary

How does Bionano Genomics compare to VivoSim Labs?

Summary

How does Bionano Genomics compare to Telesis Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNGO vs. The Competition

Bionano Genomics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bionano Genomics (BNGO) Competitors

BNGO vs. HBIO, BFRG, ISPC, VIVS, and TBIO

How does Bionano Genomics compare to Harvard Bioscience?

Which has preferable valuation and earnings, BNGO or HBIO?

Which has more volatility and risk, BNGO or HBIO?

Do analysts prefer BNGO or HBIO?

Is BNGO or HBIO more profitable?

Does the media refer more to BNGO or HBIO?

Do insiders and institutionals hold more shares of BNGO or HBIO?

Summary

How does Bionano Genomics compare to Bullfrog AI?

Which has more volatility and risk, BFRG or BNGO?

Do insiders & institutionals believe in BFRG or BNGO?

Is BFRG or BNGO more profitable?

Do analysts recommend BFRG or BNGO?

Does the media favor BFRG or BNGO?

Which has stronger earnings and valuation, BFRG or BNGO?

Summary

How does Bionano Genomics compare to iSpecimen?

Does the media prefer ISPC or BNGO?

Which has preferable earnings and valuation, ISPC or BNGO?

Do analysts recommend ISPC or BNGO?

Which has more volatility and risk, ISPC or BNGO?

Is ISPC or BNGO more profitable?

Do institutionals & insiders believe in ISPC or BNGO?

Summary

How does Bionano Genomics compare to VivoSim Labs?

Does the media favor VIVS or BNGO?

Do insiders and institutionals have more ownership in VIVS or BNGO?

Which has stronger earnings & valuation, VIVS or BNGO?

Do analysts prefer VIVS or BNGO?

Is VIVS or BNGO more profitable?

Which has more volatility & risk, VIVS or BNGO?

Summary

How does Bionano Genomics compare to Telesis Bio?

Which has higher valuation & earnings, BNGO or TBIO?

Is BNGO or TBIO more profitable?

Do analysts rate BNGO or TBIO?

Do institutionals and insiders hold more shares of BNGO or TBIO?

Does the media prefer BNGO or TBIO?

Which has more risk & volatility, BNGO or TBIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNGO vs. The Competition

Bionano Genomics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools